Travoprost Intracameral Implant Reduces Glaucoma Treatment Burden Through 36 Months - Ophthalmology Advisor Researchers compared the medication burden of an intracameral implant and a topical IOP-lowering drop.

#AAO2025: A sustained-release #Travoprost intracameral implant significantly reduced the need for topical #IOP–lowering medications compared with timolol through 36 months in patients with open-angle #Glaucoma or #OcularHypertension. Presented at AAO 2025.

Read more: https://bit.ly/3L1ELy0

#MedSky